{"pmid":32449676,"title":"COVID-19: Pentoxifylline as a potential adjuvant treatment.","text":["COVID-19: Pentoxifylline as a potential adjuvant treatment.","Int J Clin Pharmacol Ther","Feily, Amir","Daneshpay, Kian","Alighadr, Arash","32449676"],"journal":"Int J Clin Pharmacol Ther","authors":["Feily, Amir","Daneshpay, Kian","Alighadr, Arash"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32449676","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.5414/CP203782","e_drugs":["Pentoxifylline"],"topics":["Treatment"],"weight":1,"_version_":1667785213940334592,"score":9.490897,"similar":[{"pmid":32473070,"title":"Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?","text":["Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?","The world is facing a viral pandemic of a new coronavirus called COVID-19. Pentoxifylline is a methyl-xanthine and it inhibits phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti-inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID-19 and the probable benefits of Pentoxifylline against COVID-19 pathogenesis, in Medline, Scopus, Web of Sciences and Google Scholar up to March 20, 2020 with proper keywords including: pentoxifylline, Pentoxil, COVID-19, coronavirus, treatment, anti-inflammatory, immunomodulatory, anti-fibrosis, oxygenation, circulation, bronchodilator, ARDS and organ failure. We found many confirmatory data on proper efficacy of pentoxifylline n controlling COVID-19 and its consequences. The antiviral, anti-inflammatory, anti-oxidative, immune-modulatory, bronchodilator and respiratory supportive effects and protective roles in organ failures of PTX, along with its main functions means better circulation-oxygenation properties, low price and safety, make it a promising drug to be considered for covid-19 treatment, especially as an adjuvant therapy in combination with other drugs. This article is protected by copyright. All rights reserved.","Dermatol Ther","Seirafianpour, Farnoosh","Mozafarpoor, Samaneh","Fattahi, Nima","Sadeghzadeh-Bazargan, Afsaneh","Hanifiha, Melika","Goodarzi, Azadeh","32473070"],"abstract":["The world is facing a viral pandemic of a new coronavirus called COVID-19. Pentoxifylline is a methyl-xanthine and it inhibits phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti-inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID-19 and the probable benefits of Pentoxifylline against COVID-19 pathogenesis, in Medline, Scopus, Web of Sciences and Google Scholar up to March 20, 2020 with proper keywords including: pentoxifylline, Pentoxil, COVID-19, coronavirus, treatment, anti-inflammatory, immunomodulatory, anti-fibrosis, oxygenation, circulation, bronchodilator, ARDS and organ failure. We found many confirmatory data on proper efficacy of pentoxifylline n controlling COVID-19 and its consequences. The antiviral, anti-inflammatory, anti-oxidative, immune-modulatory, bronchodilator and respiratory supportive effects and protective roles in organ failures of PTX, along with its main functions means better circulation-oxygenation properties, low price and safety, make it a promising drug to be considered for covid-19 treatment, especially as an adjuvant therapy in combination with other drugs. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Seirafianpour, Farnoosh","Mozafarpoor, Samaneh","Fattahi, Nima","Sadeghzadeh-Bazargan, Afsaneh","Hanifiha, Melika","Goodarzi, Azadeh"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473070","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/dth.13733","keywords":["ards (acute respiratory distress syndrome)","covid-19","pentoxil","sars (severe acute respiratory syndrome)","anti-fibrosis","anti-inflammatory","anti-oxidant","apoptosis-regulatory","bronchodilator","coronavirus","immunomodulatory","oxygenation","pentoxifylline","perfusion","review","treatment"],"locations":["Medline","Scopus"],"topics":["Treatment"],"weight":1,"_version_":1668255193285787648,"score":80.18324},{"pmid":32485316,"pmcid":"PMC7260530","title":"Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.","text":["Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.","Med Hypotheses","Assimakopoulos, Stelios F","Seintis, Fotios","Marangos, Markos","32485316"],"journal":"Med Hypotheses","authors":["Assimakopoulos, Stelios F","Seintis, Fotios","Marangos, Markos"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32485316","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.mehy.2020.109926","e_drugs":["Pentoxifylline"],"topics":["Treatment"],"weight":1,"_version_":1668704334391541761,"score":44.62832},{"pmid":32217117,"pmcid":"PMC7102583","title":"COVID-19: Melatonin as a potential adjuvant treatment.","text":["COVID-19: Melatonin as a potential adjuvant treatment.","This article summarizes the likely benefits of melatonin in the attenuation of COVID-19 based on its putative pathogenesis. The recent outbreak of COVID-19 has become a pandemic with tens of thousands of infected patients. Based on clinical features, pathology, the pathogenesis of acute respiratory disorder induced by either highly homogenous coronaviruses or other pathogens, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response very likely contribute to COVID-19 pathology. This leads to a cytokine storm and subsequent progression to acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and often death. Melatonin, a well-known anti-inflammatory and anti-oxidative molecule, is protective against ALI/ARDS caused by viral and other pathogens. Melatonin is effective in critical care patients by reducing vessel permeability, anxiety, sedation use, and improving sleeping quality, which might also be beneficial for better clinical outcomes for COVID-19 patients. Notably, melatonin has a high safety profile. There is significant data showing that melatonin limits virus-related diseases and would also likely be beneficial in COVID-19 patients. Additional experiments and clinical studies are required to confirm this speculation.","Life Sci","Zhang, Rui","Wang, Xuebin","Ni, Leng","Di, Xiao","Ma, Baitao","Niu, Shuai","Liu, Changwei","Reiter, Russel J","32217117"],"abstract":["This article summarizes the likely benefits of melatonin in the attenuation of COVID-19 based on its putative pathogenesis. The recent outbreak of COVID-19 has become a pandemic with tens of thousands of infected patients. Based on clinical features, pathology, the pathogenesis of acute respiratory disorder induced by either highly homogenous coronaviruses or other pathogens, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response very likely contribute to COVID-19 pathology. This leads to a cytokine storm and subsequent progression to acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and often death. Melatonin, a well-known anti-inflammatory and anti-oxidative molecule, is protective against ALI/ARDS caused by viral and other pathogens. Melatonin is effective in critical care patients by reducing vessel permeability, anxiety, sedation use, and improving sleeping quality, which might also be beneficial for better clinical outcomes for COVID-19 patients. Notably, melatonin has a high safety profile. There is significant data showing that melatonin limits virus-related diseases and would also likely be beneficial in COVID-19 patients. Additional experiments and clinical studies are required to confirm this speculation."],"journal":"Life Sci","authors":["Zhang, Rui","Wang, Xuebin","Ni, Leng","Di, Xiao","Ma, Baitao","Niu, Shuai","Liu, Changwei","Reiter, Russel J"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32217117","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.lfs.2020.117583","keywords":["covid-19","cytokines","immunomodulation","melatonin","oxidation-reduction","sars-cov-2"],"e_drugs":["Melatonin"],"topics":["Treatment"],"weight":1,"_version_":1666138492316418048,"score":44.16471},{"pmid":32334009,"pmcid":"PMC7195414","title":"Correspondence COVID-19: Melatonin as a potential adjuvant treatment.","text":["Correspondence COVID-19: Melatonin as a potential adjuvant treatment.","Life Sci","Salles, Cristina","32334009"],"journal":"Life Sci","authors":["Salles, Cristina"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32334009","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.lfs.2020.117716","e_drugs":["Melatonin"],"topics":["Treatment"],"weight":1,"_version_":1666138493983653888,"score":42.068726}]}